Reply To: Avacta

#5834
Nick Hargrave
Keymaster

https://www.investormeetcompany.com/meetings/review-of-the-ava6000-clinical-trials-phase-1a-data

Q&A from the December shareholder presentation published. Obviously there is a need to read between some lines but this once again highlights the potential value of the platform that remains seemingly well hidden from the market. Commercial deals licensing the Pre-Cision platform to generate non-dilutive funding to advance its own lead assets are the catalyst the market likely needs to take notice